December 21, 2016
2016 was a very busy year for the ITN, with a total of 212 new participants in actively-enrolling trials, up from 175 new participants in 2015, and over 5000 participant study visits, the largest number ever. This robust number resulted from significant gains for PAUSE (completing enrollment in April), CATNIP, OPTIMAL, EXTEND, and CALIBRATE. A better indicator of the overall level of activity this year, there were 387 screened participants for active trials, a testament to all the hard work put in by site staff and ITN internal teams to meet enrollment targets.
Following a few concept-heavy steering committee meetings, the ITN's pipeline is very full with lots of projects to get off the ground in 2017. As of December 2016 there are 12 trials in development (TEACH, EXTEND-P, REMIX-B, LEAP-TRIO, GLASS GLA, LiTTMUS at MGH and UCSF, BRAVOS, FEAST, aHSCT-MS, C-section Microbiome, belimumab + rituximab in membranous glomerulonephritis), 8 trials in enrollment (CALIBRATE, OPTIMAL, CATNIP, EXTEND, ALLTOL, T1DES, deLTa, TILT), plus 19 trials in follow-up or analysis.
ITN had 30 publications in 2016; Highlights this year included:
Other publications included the primary results from the ACCLAIM study (abatacept in multiple sclerosis), five-year outcomes from the WISP-R study (immunosuppression withdrawal in pediatric liver transplant recipients), and an analysis of glycemic variability and C-peptide preservation from the T1DAL study (alefacept in type 1 diabetes).
ITN also rolled out a new specimen tracking system, LabVantage, at 107 clinical sites with no major issues to date, a huge accomplishment. So far the feedback from site users has been very positive.
Thanks to the entire ITN team for significant progress in all areas of the portfolio, and we look forward to another productive and exciting year in 2017.
More Information